Equities

Windlas Biotech Ltd

WINDLAS:NSI

Windlas Biotech Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)879.45
  • Today's Change20.45 / 2.38%
  • Shares traded61.32k
  • 1 Year change+149.84%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 11:22 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments2,0451,3201,787
Total Receivables, Net1,3771,1741,171
Total Inventory632762613
Prepaid expenses9.841013
Other current assets, total249269232
Total current assets4,3133,5353,817
Property, plant & equipment, net1,8031,227983
Goodwill, net------
Intangibles, net45158.82
Long term investments----0.01
Note receivable - long term------
Other long term assets4710478
Total assets6,2625,2904,910
LIABILITIES
Accounts payable1,315877632
Accrued expenses304256218
Notes payable/short-term debt000
Current portion long-term debt/capital leases161962
Other current liabilities, total826028
Total current liabilities1,7171,212940
Total long term debt20314.44
Total debt365066
Deferred income tax----0
Minority interest------
Other liabilities, total252318
Total liabilities1,7631,267962
SHAREHOLDERS EQUITY
Common stock104105109
Additional paid-in capital1,9461,9862,269
Retained earnings (accumulated deficit)2,4011,9041,551
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.41)(0.36)(0.06)
Total equity4,4994,0233,948
Total liabilities & shareholders' equity6,2625,2904,910
Total common shares outstanding212122
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.